SCHEMBL10074155

SCHEMBL10074155

NC(Cc1cc(F)ccc1F)CS(=O)(=O)NCCCCNC(=O)C(O)C(N)Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LAP3 P28838 3/20 0.46
ANPEP P15144 1/20 0.46
RNPEP Q9H4A4 1/20 0.46
DNPEP Q9ULA0 1/20 0.46
METAP2 P50579 2/20 0.38
RAB9A P51151 1/20 0.38
DPP4 P27487 4/20 0.38
DPP7 Q9UHL4 3/20 0.38
RORC P51449 1/20 0.37
DPP9 Q86TI2 2/20 0.36
HDAC8 Q9BY41 1/20 0.35
REN P00797 1/20 0.35
F2 P00734 1/20 0.35
CHRNA1 P02708 1/20 0.35
CHRNG P07510 1/20 0.35
CHRNB1 P11230 1/20 0.35
CHRND Q07001 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10077373 0.88 LAP3 (0.36) LAP3ANPEPRNPEPDNPEPMETAP2
SCHEMBL10078089 0.87 LAP3 (0.45) LAP3ANPEPRNPEPDNPEPMETAP2
SCHEMBL10077078 0.87 LAP3 (0.45) LAP3ANPEPRNPEPDNPEPMETAP2
SCHEMBL10077380 0.85 LAP3 (0.42) LAP3ANPEPRNPEPDNPEPMETAP2
SCHEMBL6873752 0.85 LAP3 (0.49) LAP3ANPEPRNPEPDNPEPMETAP2
SCHEMBL6873314 0.83 LAP3 (0.49) LAP3ANPEPRNPEPDNPEPMETAP2
SCHEMBL10074275 0.82 LAP3 (0.50) LAP3ANPEPRNPEPDNPEPMETAP2
SCHEMBL10074349 0.82 MMP2 (0.50) LAP3ANPEPRNPEPDNPEPMETAP2
SCHEMBL10074145 0.82 MMP2 (0.50) LAP3ANPEPRNPEPDNPEPMETAP2
SCHEMBL6873883 0.81 LAP3 (0.51) LAP3ANPEPRNPEPDNPEPMETAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2418196-A1 Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors IMTM GmbH (DE) 2012-02-15 EP disclosed
US-20120028995-A1 NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS IMTM GMBH (DE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028995-A1 NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS SERPINB1, CMA1, CPA3 LAP3 186/4885ANPEP 36/4885RNPEP 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.